HOMA-IR: what it measures, symptoms, consequences and reversal

By Guillermo Salinas Araya · June 1, 2026 · Educational material

In 1988, Gerald Reaven delivered the Banting Lecture at the American Diabetes Association introducing the concept of Syndrome X — what we now recognize as insulin resistance. That lecture changed cardiology, endocrinology, and hepatology forever.

Medical definition of HOMA-IR

The term HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) refers to a clinical condition with diagnostic criteria established in recent medical literature. Understanding it requires distinguishing between the entity itself, its forms of presentation, and its underlying mechanisms. Updated international guidelines have reformulated several of these criteria over the past decade, expanding what conventional clinical practice has not yet incorporated.¹

Pathophysiology: how it develops

The pathophysiological cascade of insulin resistance involves multiple parallel mechanisms that feed back into each other. The monocausal hypothesis has been replaced by integrative models that recognize the interaction of several axes:²

• Endocrine-metabolic axis: impairment of insulin sensitivity and hepatic lipogenesis.
• Inflammatory axis: low-grade pro-inflammatory cytokines (TNF-α, IL-6, elevated high-sensitivity CRP).
• Mitochondrial axis: dysfunction of the respiratory chain and increased reactive oxygen species.
• Intestinal axis: altered microbiome, increased intestinal permeability, endotoxin translocation.
• Neuroendocrine axis: dysregulation of the hypothalamic-pituitary-adrenal axis with chronically elevated cortisol.

The simultaneous accumulation of these five impacts is what distinguishes the pathological state from the physiological state of compensatory tolerance. A patient may go years with one or two active axes without clinical manifestation — until the convergence overwhelms adaptive mechanisms.

Clinical signs and symptoms

Clinical presentation is heterogeneous. In early phases, most patients are oligosymptomatic or asymptomatic.³ Signs and symptoms that guide diagnosis include:

• Unexplained fatigue, especially postprandial
• Progressive increase in waist circumference
• Skin changes (dark patches, skin tags, hair alterations)
• Sleep-wake cycle disturbances
• Neurocognitive symptoms: brain fog, difficulty concentrating, irritability
• Nonspecific laboratory findings: slightly elevated CRP, mild liver enzyme or lipid abnormalities frequently categorized as "high normal"
• Subtle ultrasound findings requiring targeted examination

Consequences if left unaddressed

The natural history of HOMA-IR without adequate intervention involves silent but predictable progression:⁴

• Increased cardiovascular risk independent of cholesterol
• Accelerated development of type 2 diabetes in patients with prediabetes
• Progression to structural organ damage within 5 to 15 years
• Increased cancer risk documented in longitudinal cohorts
• Progressive functional deterioration reducing quality of life and healthy life expectancy

The therapeutic opportunity window — the period during which the condition is completely reversible — is proportional to the duration of exposure and the number of compromised pathophysiological axes. Each year lost without comprehensive intervention narrows that window.

Can it be reversed?

Contemporary clinical evidence is compelling: in pre-irreversible stages, reversal is possible. But it requires addressing all five pathophysiological axes simultaneously, not sequentially or in isolation. This is where conventional approaches fail: they intervene on a single axis and leave the other four active.

The educational protocol we designed — The Salinas Method — includes 8 sequential phases. Each phase addresses a distinct mechanism in the cascade. Phases 1 and 2 prepare the cellular terrain and correct the microbiome. Phases 3 through 6 dismantle low-grade inflammation, mitochondrial dysfunction, insulin resistance, and cortisol axis disruption. Phases 7 and 8 consolidate the change and prevent relapse.

It's not a diet. It's not isolated fasting. It's not a supplement. It's a step-by-step guided educational protocol, based on the most recent clinical evidence and designed so patients understand the rationale behind each action.

References

1. DeFronzo RA. Insulin resistance: a multifaceted syndrome. Diabetes Care. 1991. PubMed
2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988. PubMed
3. Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function. Diabetologia. 1985. PubMed
4. Petersen KF, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018. PubMed
5. Stumvoll M, et al. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005. PubMed
6. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways. Cell. 2012. PubMed

100% educational material. Does not replace consultation with a qualified healthcare professional.